The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME

  • Authors:
    • Luca Vanella
    • Claudia Di Giacomo
    • Rosaria Acquaviva
    • Rosa Santangelo
    • Venera Cardile
    • Ignazio Barbagallo
    • Nader G. Abraham
    • Valeria Sorrenti
  • View Affiliations

  • Published online on: June 30, 2011     https://doi.org/10.3892/ijo.2011.1107
  • Pages: 1303-1310
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Benign prostate hypertrophy (BPH) and prostate cancer (PC) are prostate chronic diseases that require a long period for development from a small lesion to clinical manifestation. PC is the most common cancer in men in Europe and the Americas. Tumor growth and metastasis depend upon the development of neovasculature around the tumor. This process, called angiogenesis, may be regulated by NO, and thus modulation of NO production could play an important role in tumor progression. Recent studies report the involvement of DDAH, an enzyme which metabolizes the endogenous NOS inhibitor ADMA, in the development of tumor vasculature. The aim of the present study was to verify the involvement of the DDAH/NOS pathway in the progression of prostate cancer. The effect of the NOS inhibitor L-NAME was evaluated in the human prostate cancer cell line LnCap and in BPH-1 cells which represent benign prostatic hypertrophy. Higher DDAH-2, eNOS, iNOS and VEGF expression was found in LnCap cells compared to BPH-1 cells. L-NAME treatment of LnCap cells resulted in a reduction in VEGF, iNOS and eNOS expression. VEGF, iNOS and eNOS inhibition is a promising approach for targeting tumor vasculature and certain NOS inhibitors could potentially serve as experimental agents for treatment of certain chemoresistant tumors, including prostate tumors. Moreover, since in our experimental conditions L-NAME was unable to reduce DDAH activity and expression, it is plausible to hypothesize the development of a targeted polypharmacological approach by developing dual and specific inhibitors of DDAH and NOS to better control NO biosynthesis.

Related Articles

Journal Cover

November 2011
Volume 39 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Vanella, L., Di Giacomo, C., Acquaviva, R., Santangelo, R., Cardile, V., Barbagallo, I. ... Sorrenti, V. (2011). The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME. International Journal of Oncology, 39, 1303-1310. https://doi.org/10.3892/ijo.2011.1107
MLA
Vanella, L., Di Giacomo, C., Acquaviva, R., Santangelo, R., Cardile, V., Barbagallo, I., Abraham, N. G., Sorrenti, V."The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME". International Journal of Oncology 39.5 (2011): 1303-1310.
Chicago
Vanella, L., Di Giacomo, C., Acquaviva, R., Santangelo, R., Cardile, V., Barbagallo, I., Abraham, N. G., Sorrenti, V."The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME". International Journal of Oncology 39, no. 5 (2011): 1303-1310. https://doi.org/10.3892/ijo.2011.1107